Steris (NYSE:STE)‘s stock had its “market perform” rating reaffirmed by stock analysts at Raymond James Financial in a research report issued on Wednesday. They presently have a $100.00 target price on the medical equipment provider’s stock. Raymond James Financial’s price target points to a potential upside of 15.49% from the stock’s previous close.
Several other equities analysts have also recently issued reports on STE. Zacks Investment Research raised Steris from a “hold” rating to a “buy” rating and set a $101.00 price objective for the company in a report on Monday, October 9th. KeyCorp reissued a “buy” rating and issued a $91.00 price objective on shares of Steris in a report on Tuesday, October 17th. Finally, TD Securities boosted their price objective on Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Steris has a consensus rating of “Buy” and an average price target of $79.50.
Shares of Steris (NYSE:STE) traded down $0.55 during mid-day trading on Wednesday, hitting $86.59. The stock had a trading volume of 400,600 shares, compared to its average volume of 425,667. The firm has a market cap of $7,411.46, a PE ratio of 51.54 and a beta of 1.27. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. Steris has a fifty-two week low of $65.26 and a fifty-two week high of $93.39.
Steris (NYSE:STE) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.95 by ($0.01). The company had revenue of $634.20 million during the quarter, compared to analyst estimates of $629.02 million. Steris had a net margin of 5.59% and a return on equity of 11.49%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm earned $0.89 EPS. research analysts expect that Steris will post 4.06 EPS for the current year.
In related news, insider Michael J. Tokich sold 11,000 shares of the company’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $92.00, for a total value of $1,012,000.00. Following the completion of the transaction, the insider now owns 58,588 shares of the company’s stock, valued at approximately $5,390,096. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP John Adam Zangerle sold 3,650 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total value of $321,200.00. The disclosure for this sale can be found here. Corporate insiders own 2.55% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STE. Zions Bancorporation acquired a new position in Steris in the 3rd quarter worth about $178,000. Citigroup Inc. acquired a new position in Steris in the 2nd quarter worth about $206,000. BT Investment Management Ltd acquired a new position in Steris in the 2nd quarter worth about $210,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Steris by 10.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,276 shares of the medical equipment provider’s stock worth $267,000 after purchasing an additional 311 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Steris in the 3rd quarter worth about $284,000. 89.40% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Steris (STE) Rating Reiterated by Raymond James Financial” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2018/01/05/steris-ste-rating-reiterated-by-raymond-james-financial.html.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.